An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgarus are treated with s.c. methotrexat using an optimized treatment schedule, Phase III, (EUDRACT-No 2012-002716-10)

2014

A phase IIa, 28-day treatment, multi-center, randomized, comparator-controlled, observer-blind trial with an intra-individual left/right comparison to investigate the anti-psoriatic efficacy and the safety of an LAS41004 formulation in comparison to an active reference in patients with mild to moderate plaque psoriasis, EUDRACT-No 2013-003757-22

2014

A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group comparison. EUDRACT-No. 2013-004519-28

2015

Open-label study to asses the tolerance and efficacy of the product RV4421A BS0042, applied in paediatric and adult populations with mild to moderate atopic dermatitis for three weeks MEDICAL PRODUCT RV4421A2013428

2016

A multicenter, randomized, double-blind, parallel, vehicl-controlled study to evaluate the efficacy and safety of P-3058 10% nail solution in the treatment of onychomycosis. EUDRACT-No. 2015-000561-31